You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for (RS)-3,4-DCPG
(RS)-3,4-DCPG is a systemically active anticonvulsant that is 30-100-fold more potent in vivo than the separate enantiomers (S)-3,4-DCPG or (R)-3,4,-DCPG.
Technical Data for (RS)-3,4-DCPG
|Storage||Desiccate at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for (RS)-3,4-DCPG
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions for (RS)-3,4-DCPG
The following data is based on the product molecular weight 239.18. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||8.36 mL||41.81 mL||83.62 mL|
|2.5 mM||1.67 mL||8.36 mL||16.72 mL|
|5 mM||0.84 mL||4.18 mL||8.36 mL|
|25 mM||0.17 mL||0.84 mL||1.67 mL|
References for (RS)-3,4-DCPG
References are publications that support the biological activity of the product.
Moldrich et al (2001) Anticonvulsant activity of 3,4-dicarboxyphenylglycines in DBA/2 mice. Neuropharmacology 40 732 PMID: 11311902
Thomas et al (1997) Dicarboxyphenylglycines antagonize AMPA- but not kainate-induced depolarizations in neonatal rat motoneurones. Eur.J.Pharmacol. 338 111 PMID: 9455991
Thomas et al (1998) Pharmacological differentiation of kainate receptors on neonatal rat spinal motoneurones and dorsal roots. Neuropharmacology 37 1223 PMID: 9849660
If you know of a relevant reference for (RS)-3,4-DCPG, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: (RS)-3,4-DCPG, (RS)-3,4-DCPG supplier, Potent, systemically, active, anticonvulsant, Racemate, Glutamate, Ionotropic, Non-Selective, iGlur, Receptors, Group, III, mGluR8, mGlu8, Metabotropic, antagonists, Non-selective, (Metabotropic), 1394, Tocris Bioscience
1 Citation for (RS)-3,4-DCPG
Citations are publications that use Tocris products. Selected citations for (RS)-3,4-DCPG include:
Gosnell et al (2011) mGluR8 modulates excitatory transmission in the bed nucleus of the stria terminalis in a stress-dependent manner. Neuropsychopharmacology 36 1599 PMID: 21451497
Do you know of a great paper that uses (RS)-3,4-DCPG from Tocris? Please let us know.
Reviews for (RS)-3,4-DCPG
There are currently no reviews for this product. Be the first to review (RS)-3,4-DCPG and earn rewards!
Have you used (RS)-3,4-DCPG?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.